# PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

> **NCT07429240** · PHASE1,PHASE2 · RECRUITING · sponsor: **Precision BioSciences, Inc.** · enrollment: 18 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

## Interventions

- **BIOLOGICAL:** PBGENE-DMD (IV)

## Key facts

- **NCT ID:** NCT07429240
- **Lead sponsor:** Precision BioSciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-24
- **Primary completion:** 2029-11
- **Final completion:** 2029-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07429240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07429240, "PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07429240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*